THE SCIENCE

We show our work.

Every compound OVA carries is broken down by mechanism, research, female-specific considerations, and honest limitations.

This isn’t marketing copy. It’s the research, translated.

WHY FEMALE BIOLOGY MATTERS

Peptide research has a gender problem.

were The majority of peptide studies particularly the preclinical data conducted on male subjects or male mice. When female subjects are included, cycle phase, hormonal status, and body composition differences are rarely controlled for.

This matters because:

DOSING:

BPC-157 is dosed at 2.5-3.75 mcg/kg. A 60kg woman needs a meaningfully different dose than a 90kg man community protocols don't account for this. and most

TIMING:

GH secretion varies across the menstrual cycle. GHK-Cu's collagen-synthesis effect may be amplified during the follicular phase when estrogen is rising.

INTERACTIONS:

Tirzepatide reduces oral contraceptive absorption by up to 20%. Most peptide guides don't mention this.

SIDE EFFECTS:

GLP-1 side effects (nausea, Gl sensitivity) are frequently more pronounced during the luteal phase. Knowing this changes how you titrate.

OVA accounts for all of this. Every product page includes female-specific dosing notes, cycle-phase guidance where evidence exists, and contraceptive interaction disclosures where relevant.
COMPOUND INDEX

(Each card links to a full compound deep-dive page)

GHK-Cu (Copper Peptide)

THE GLOW COLLECTION

Mechanism: Stimulates collagen synthesis, promotes angiogenesis, upregulates wound healing genes.

Female relevance: Collagen loss accelerates up to 30% in the first 5 years post-menopause. GHK-Cu directly addresses this pathway.

Evidence: 71-woman clinical study — daily topical application for 3 months significantly increased skin density and reduced sagging.

BPC-157

THE REPAIR COLLECTION / THE GLOW COLLECTION

Mechanism: Gastric-derived body protection compound. Promotes angiogenesis, tissue repair, and gut barrier integrity.

Female relevance: Non-hormonal. No virilization risk. Most commonly recommended first peptide for women.

Female dosing: Start at 200–250 mcg/day (lower than male-default community dosing).

Tirzepatide

THE FORM COLLECTION

Mechanism: Dual GIP/GLP-1 receptor agonist. Suppresses appetite, slows gastric emptying, improves insulin sensitivity.

Female relevance: Women consistently lose more weight on GLP-1 agonists than men in matched studies — likely due to hormonal interactions. 15.3% average weight loss at 12 months.

Key interaction: Reduces oral contraceptive bioavailability by up to 20%. Use barrier contraception for 4 weeks after each dose increase.

Epithalon

THE LONGEVITY COLLECTION

Mechanism: Synthetic tetrapeptide that activates telomerase — the enzyme responsible for maintaining telomere length.

Protocol: Standard “Ukrainian cycle” — 10mg daily for 20 days, 2x per year.

Female relevance: Telomere shortening accelerates post-menopause. Epithalon is among the most studied longevity peptides in Eastern European clinical research.

Selank

THE CLARITY COLLECTION

Mechanism: Tuftsin analog. Modulates GABA, serotonin, and dopamine pathways. Anxiolytic and nootropic effects.

Female relevance: Brain fog and anxiety are the most commonly reported cognitive symptoms of perimenopause. Selank addresses both pathways without the sedation profile of pharmaceutical anxiolytics.

Kisspeptin-10

THE CYCLE COLLECTION

Mechanism: Hypothalamic neuropeptide that triggers GnRH release and regulates the HPG (hypothalamic-pituitary-gonadal) axis.

Female relevance: Clinical data supports use in women with hypothalamic amenorrhea, PCOS, and hormonal dysregulation. One of the few peptides with meaningful human female trial data.